Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.62 |
| ▸ | EPHA2 | P29317 | 4/20 | 0.62 |
| ▸ | CASP7 | P55210 | 3/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.62 |
| ▸ | VDR | P11473 | 3/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | BLM | P54132 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | USP2 | O75604 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MDM4 | O15151 | 1/20 | 0.62 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.62 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26601020 | 1.00 | GPBAR1 (0.62) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL26600654 | 0.91 | GPBAR1 (0.60) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL26600649 | 0.91 | GPBAR1 (0.60) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL26670009 | 0.89 | GPBAR1 (0.77) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL235606 | 0.89 | GPBAR1 (0.77) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL235607 | 0.89 | GPBAR1 (0.77) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL21567088 | 0.88 | EPHA2 (0.79) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL1653772 | 0.86 | GPBAR1 (0.79) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL26669997 | 0.85 | GPBAR1 (0.59) | GPBAR1EPHA2CASP7HIF1AVDR | |
| SCHEMBL23008061 | 0.85 | GPBAR1 (0.80) | GPBAR1EPHA2CASP7HIF1AVDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | Asteroid Therapeutics (US) | 2025-10-28 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics | 2023-10-26 | — | — | US | disclosed |
| WO-2023205801-A2 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | Asteroid Therapeutics (US) | 2023-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454547-B2 | Steroidal compositions and methods of treating lipogenic cancers | SREBF1, SREBF2, NR1H3 | GPBAR1 138/4885EPHA2 1690/4885CASP7 1115/4885 |
| US-20230340011-A1 | STEROIDAL COMPOSITIONS AND METHODS OF TREATING LIPOGENIC CANCERS | SREBF1, SREBF2, NR1H3 | GPBAR1 138/4885EPHA2 1690/4885CASP7 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.